A molecular gate which controls unnatural ATP analogue recognition by the tyrosine kinase v-Src

被引:133
作者
Liu, Y
Shah, K
Yang, F
Witucki, L
Shokat, KM [1 ]
机构
[1] Princeton Univ, Dept Chem, Princeton, NJ 08544 USA
[2] Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA
关键词
kinase; rational design; ATP analogue; Src;
D O I
10.1016/S0968-0896(98)00099-6
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Engineered proteins with specificity for unnatural substrates or ligands are useful tools for studying or manipulating complex biological systems. We have engineered the prototypical tyrosine kinase v-Src to accept an unnatural ATP analogue N-6-(benzyl) ATP in order to identify v-Src's direct cellular substrates. Here we have used molecular modeling to analyze the binding mode of N-6-(benzyl) ATP. Based on this modeling we proposed that a new ATP analogue (N-6-(2-phenethyl) ATP might be a better substrate than N-6-(benzyl) ATP for the I338G mutant of v-Src. In fact the newly proposed analogue (N-6-(2-phenethyl) ATP is a somewhat improved substrate for the engineered kinase (k(cat) = 0.6 min(-1), K-M = 8 mu M). We also synthesized and screened three analogues of N-6-(benzyl) ATP: N-6-(2-methylbenzyl), ATP N-6-(3-methylbenzyl), and ATP N-6-(4-methylbenzyl) ATP to further probe the dimensions and shape of the introduced pocket. Results from screening newly synthesized ATP analogues agreed well with our modeling predictions. We conclude that rather than engineering a 'new' pocket by mutation of Ile 338 in v-Src to the smaller Ala or Gly residues, the I338G and I338A mutants possess a 'path' for the N-6 substituent on ATP to gain access to an existing pocket in the ATP binding site. We expect to be able to extend the engineering of v-Src's ATP specificity to other kinase families based on our understanding of the binding modes of ATP analogues to engineered kinases. (C) 1998 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:1219 / 1226
页数:8
相关论文
共 25 条
[1]   A versatile synthetic dimerizer for the regulation of protein-protein interactions [J].
Amara, JF ;
Clackson, T ;
Rivera, VM ;
Guo, T ;
Keenan, T ;
Natesan, S ;
Pollock, R ;
Yang, W ;
Courage, NL ;
Holt, DA ;
Gilman, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (20) :10618-10623
[2]   RATIONAL DESIGN OF ORTHOGONAL RECEPTOR-LIGAND COMBINATIONS [J].
BELSHAW, PJ ;
SCHOEPFER, JG ;
LIU, KQ ;
MORRISON, KL ;
SCHREIBER, SL .
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION IN ENGLISH, 1995, 34 (19) :2129-2132
[3]   Cell-specific calcineurin inhibition by a modified cyclosporin [J].
Belshaw, PJ ;
Schreiber, SL .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1997, 119 (07) :1805-1806
[4]   Site-specific, photochemical proteolysis applied to ion channels in vivo [J].
England, PM ;
Lester, HA ;
Davidson, N ;
Dougherty, DA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (20) :11025-11030
[5]   Tyrosine phosphorylation: Past, present and future [J].
Hunter, T .
BIOCHEMICAL SOCIETY TRANSACTIONS, 1996, 24 (02) :307-327
[6]   The protein kinases of budding yeast: Six score and more [J].
Hunter, T ;
Plowman, GD .
TRENDS IN BIOCHEMICAL SCIENCES, 1997, 22 (01) :18-22
[7]  
HWANG YW, 1987, J BIOL CHEM, V262, P1081
[8]   MECHANISM OF CDK ACTIVATION REVEALED BY THE STRUCTURE OF A CYCLINA-CDK2 COMPLEX [J].
JEFFREY, PD ;
RUSO, AA ;
POLYAK, K ;
GIBBS, E ;
HURWITZ, J ;
MASSAGUE, J ;
PAVLETICH, NP .
NATURE, 1995, 376 (6538) :313-320
[9]   PLATELET-AGGREGATION INHIBITORS .4. N-6-SUBSTITUTED ADENOSINES [J].
KIKUGAWA, K ;
IIZUKA, K ;
ICHINO, M .
JOURNAL OF MEDICINAL CHEMISTRY, 1973, 16 (04) :358-364
[10]   Inducible gene expression and protein translocation using nontoxic ligands identified by a mammalian three-hybrid screen [J].
Liberles, SD ;
Diver, ST ;
Austin, DJ ;
Schreiber, SL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (15) :7825-7830